Crescent Biopharma

Crescent Biopharma Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics for solid tumors. Its current pipeline centers on antibody-based programs, including bispecific antibodies and antibody-drug conjugates designed to address key biological pathways involved in cancer growth and progression. The company’s lead efforts include CR-001, a PD-1 x VEGF bispecific antibody, along with additional candidates aimed at treating advanced solid tumors. Crescent Biopharma Inc. operates in the highly specialized biopharmaceutical sector, where research, clinical development, and strategic collaborations are central to advancing new treatment options. The company’s role in the market is defined by its emphasis on precision-engineered cancer therapies and its focus on late-stage disease areas with significant unmet medical need.